scholarly journals 6‐Methoxyethylamino‐numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib

2017 ◽  
Vol 31 (12) ◽  
pp. 5453-5465 ◽  
Author(s):  
Yanning Liu ◽  
Guohua Lou ◽  
John T. Norton ◽  
Chen Wang ◽  
Irawati Kandela ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Single Agent ◽  
Xenograft Growth ◽  
Carcinoma Xenograft

scholarly journals Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice

Hepatology ◽  
2011 ◽  
Vol 54 (6) ◽  
pp. 2036-2047 ◽  
Author(s):  
Xin Zeng ◽  
Yong Lin ◽  
Chuan Yin ◽  
Xin Zhang ◽  
Bei-Fang Ning ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Recombinant Adenovirus ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Xenograft Growth ◽  
Carcinoma Xenograft

Sustained Complete Remission of Metastatic Hepatocellular Carcinoma with Single Agent Sorafenib

2012 ◽  
Vol 44 (1) ◽  
pp. 98-101 ◽  
Author(s):  
Premal D. Lulla ◽  
Jonathan E. Brammer ◽  
Salman Bandeali ◽  
Garret R. Lynch
Keyword(s):  
Hepatocellular Carcinoma ◽  
Complete Remission ◽  
Single Agent ◽  
Metastatic Hepatocellular Carcinoma

scholarly journals Effect of restin gene transfection on human gastric carcinoma xenograft growth in nude mice

2008 ◽  
Vol 16 (33) ◽  
pp. 3713
Author(s):  
Jian-Yong Zhang ◽  
Jin-Yi Li ◽  
Hong-Yu Li ◽  
Cong Dai ◽  
Chun-Lei Ma ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Nude Mice ◽  
Gene Transfection ◽  
Human Gastric Carcinoma ◽  
Xenograft Growth ◽  
Carcinoma Xenograft

scholarly journals Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

Oncotarget ◽  
2015 ◽  
Vol 6 (24) ◽  
pp. 20160-20176 ◽  
Author(s):  
Qingyang Gu ◽  
Bin Zhang ◽  
Hongye Sun ◽  
Qiang Xu ◽  
Yexiong Tan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Xenograft Tumor ◽  
Tumor Models ◽  
Preclinical Development ◽  
Large Panel ◽  
Genomic Characterization ◽  
Carcinoma Xenograft

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis

Cancer ◽  
2012 ◽  
Vol 118 (21) ◽  
pp. 5293-5301 ◽  
Author(s):  
Joanne Chiu ◽  
Yuen Fong Tang ◽  
Tzy-Jyun Yao ◽  
Ashley Wong ◽  
Hilda Wong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Single Agent ◽  
Advanced Hepatocellular Carcinoma

Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate

2021 ◽  
Vol 13 (579) ◽  
pp. eabb6282
Author(s):  
Fan-En Kong ◽  
Guang-Meng Li ◽  
Yun-Qiang Tang ◽  
Shao-Yan Xi ◽  
Jane Ho Chun Loong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tight Junction ◽  
Single Agent ◽  
Embryonic Stem ◽  
Tight Junction Protein ◽  
Premalignant Lesions ◽  
Phenotypic Switching ◽  
Primary Tumors ◽  
Sorafenib Treatment ◽  
Junction Protein

Tumor lineage plasticity is emerging as a critical mechanism of therapeutic resistance and tumor relapse. Highly plastic tumor cells can undergo phenotypic switching to a drug-tolerant state to avoid drug toxicity. Here, we investigate the transmembrane tight junction protein Claudin6 (CLDN6) as a therapeutic target related to lineage plasticity for hepatocellular carcinoma (HCC). CLDN6 was highly expressed in embryonic stem cells but markedly decreased in normal tissues. Reactivation of CLDN6 was frequently observed in HCC tumor tissues as well as in premalignant lesions. Functional assays indicated that CLDN6 is not only a tumor-associated antigen but also conferred strong oncogenic effects in HCC. Overexpression of CLDN6 induced phenotypic shift of HCC cells from hepatic lineage to biliary lineage, which was more refractory to sorafenib treatment. The enhanced tumor lineage plasticity and cellular identity change were potentially induced by the CLDN6/TJP2 (tight junction protein 2)/YAP1 (Yes-associated protein 1) interacting axis and further activation of the Hippo signaling pathway. A de novo anti-CLDN6 monoclonal antibody conjugated with cytotoxic agent (Mertansine) DM1 (CLDN6-DM1) was developed. Preclinical data on both HCC cell lines and primary tumors showed the potent antitumor efficiency of CLDN6-DM1 as a single agent or in combination with sorafenib in HCC treatment.

scholarly journals Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model

2020 ◽  
Vol 223 ◽  
pp. 33-43
Author(s):  
Yuwei Wu ◽  
Jinyu Wang ◽  
Xiaodong Zheng ◽  
Yongyan Chen ◽  
Mei Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Xenograft Model ◽  
Carcinoma Xenograft
Sign in / Sign up

Export Citation Format

Share Document